東京大学医科学研究所附属病院　セルプロセッシング・輸血部

研究内容

検査部・輸血部における検査技術や品質向上を目指した研究に関するお知らせ

Department of Cell Processing and Transfusion
セルプロセッシング・輸血部

　

1) Transfusion medicine and related tests:

Abe Y, Ogami K, Iwasawa N, Yokoyama K, Nagamura-Inoue T

Our department controls and supports transfusion medicine through blood typing, irregular antibody testing, and cross-matching tests on blood transfusion products including concentrated red blood cells, platelets, and frozen plasma. The blood type of some patients with hematopoietic disorders and post–stem cell transplantation is undetectable.

2) Cell Processing and quality tests for Hematopoietic stem cell transplantation and clinical trials.

Nagamura-Inoue T, Yokoyama K, Takahashi A, Ogami K, Miharu Y

For autologous peripheral blood stem cell transplantation (PBSCT), we perform apheresis for patients with myeloma and malignant lymphoma after mobilization by granulocyte colony-stimulating factor with or without the CXCR-4 inhibitor, Plerixafor. We test CD34-positive cells in the graft of PBSC, bone marrow, and cord blood as the quality tests for hematopoietic transplantations. We process the cells for clinical trials including collection (apheresis), cryopreservation, and thawing with or without washing upon the requests.

3) Exploring the therapeutic application of UC-MSCs for severe acute graft-versus-host disease (aGVHD) and non-infectious pulmonary complications (NIPC) after hematopoietic stem cell transplantation

Nagamura-Inoue T, Takahashi A, Hori A, Miharu Y, Mori Y, Nagamura F, Yokoyama K

We investigated the immunosuppressive mechanisms of UC-MSCs on inflammatory cells. A phase I dose-escalation trial, IMSUT-CORD for steroid-resistant aGVHD using allogeneic umbilical cord-derived mesenchymal stromal cells (IMSUT-CORD) have been safely completed (Int J Hematol. 2022 Nov;116(5):754-769.). From 2022 to 2023, clinical trial of NIPC treated with UC-MSCs have been implemented. We continued to prepare the next clinical trials by obtaining the pre-clinical POC for aGVHD and NIPC in vitro and in vivo.

4) Study of therapeutic application of UC-MSCs to acute brain injury and importance of microglia

Sei K, Mori Y, Mukai T, Nagamura-Inoue T

Based on the efficacy of proof of concept using UC-MSCs for cerebral palsy by Mukai T et al, a clinical trial (Phase I/II) for cerebral palsy treated with UC-MSCs was implemented from 2021 to 2023, and completed safely. Furthermore, we investigated the efficiency of UC-MSCs for the treatment of acute encephalitis (AE) mimicking the viral encephalitis. We found the improvement of the neuron degeneration and part of behavior abnormalities in AE by intravenous injection of UC-MSCs.

5) Research and Development of UC-MSCs treatment for new application of UC-MSCs to acute radiation injury, cleft palate, and hemorrhagic arthropathy

Mori Y, Takahashi A, Miharu Y, Hori A, Nagamura-Inoue T,

We have been exploring UC-MSCs (IMSUT-CORD) treatment for new application of UC-MSCs to acute radiation injury, cleft palate, and hemorrhagic arthropathy using mice models in collaboration with companies.

6) The Research Cord Blood Cell Resource / National BioResource Project (NBRP)

Yamaura N, Yoshino T, Miharu Y, Takahashi A, Nagaya N, Nagamura-Inoue T

The Research Cord Blood bank / resource was established in 2004 and supported by the Ministry of Education, Culture, Sports, Science and Technology for the development of regenerative medicine, immunological cell therapy, infection research, modified gene cell therapy, and drug discovery. Since July 2012, this project has been incorporated into the National BioResource Project (NBRP). The research umbilical cord blood (CB) bank provides processed and cryopreserved CB units (nucleated cells, mononuclear cells, and CD34+ cells) to researchers worldwide via the RIKEN Bioresource Center. The website is at http://www.nbrp.jp/.

Institute of Medical Science, University of Tokyo, Cell Resource Center (IMSUT-CRC)
東大医科研細胞リソースセンター

Takahashi A, Miharu Y, Hori A, Mori Y, Yamaura N, Nagamura-Inoue T

To promote cell therapy in translational research, IMSUT-CRC was established in 1997 (originally called the Room for Clinical Cellular Technology, or RCCT). To date, the following projects have been implemented:1) CB cell processing for banking in the manner of the Tokyo Cord Blood Bank (1997–2008), 2) research cord blood bank (2004–), 3) dendritic cell therapies (1998–2001), 4) regenerative therapy of alveolar bone derived from bone marrow mesenchymal cells (2005– 2011), 5) gene therapy for renal cancer (1998), 6) CB and UC-MSC banking (IMSUT-CORD; 2012–), 6)aAVC-WT1 cell therapy (2017–), and (7) dendritic cell(DC) therapy using DCs pulsed with neoantigen(2020–). Visit our website: http: //www.ims.u-tokyo.ac.jp/dcpt/english/.

Center for Stem Cell Biology and Regenerative Medicine, Division of Somatic Stem Cell Research
体性幹細胞研究分野

HPはこちら

Somatic stem cells, which are derived from mesoderm, include mesenchymal stromal cells (MSCs), blood cells, and other mesenchymal tissues. MSCs exist in the interstitium of systemic organs; they have self-renewal ability, migrate to the sites of inflammation and tissue damage, and exert anti-inflammatory effects and tissue-repair ability. Among various somatic stem cells, we focused on umbilical cord blood (CB) and umbilical cord-derived MSCs (UC-MSCs) and we explored new immune and regenerative gene/cell therapies using CB and UC-MSCs. Another mission is to manage the IMSUT-HLC cell processing facility (IMSUT-HLC- CPF) for translational research. To achieve the high-quality processing and tests for UC-MSCs therapy, IMSUT-HLC-CPF obtained manufacturing license as the first national University in 2023.

7) Cord blood and umbilical cord–derived cells for immune-cell therapy and regenerative medicine

Sudo K, Takahashi A, Hori A, Miharu Y, Nagaya N, Mori Y, Ogami K, Nagamura-Inoue T

We explored new immune and regenerative gene/ cell therapies using umbilical cord blood (CB) and umbilical cord-derived MSCs (UC-MSCs) with high quality and safety standards. For the high quality and safety standards. In addition, it is our mission to keep the IMSUT-HLC cell processing facility clean and functional to enable high-quality manufacturing for translation- al gene and cell therapy. To achieve this mission IMSUT-HLC-CPF obtained manufacturing license for UC-MSCs therapy as the first national University in 2023.

Publications

1) Iwai T, Ikeguchi R, Aoyama T, Noguchi T, Yoshimoto K, Sakamoto D, Fujita K, Miyazaki Y, Akieda S, Nagamura-Inoue T, Nagamura F, Nakayama K, Matsuda S. Nerve regeneration using a Bio 3D conduit derived from umbilical cord-Derived mesenchymal stem cells in a rat sciatic nerve defect model. PLoS One. 2024 Dec 23;19(12):e0310711. doi: 10.1371/journal.pone.0310711. eCollection 2024. PMID: 39715170
2) Iwatake M, Nagamura-Inoue T, Doi R, Tanoue Y, Ishii M, Yukawa H, Matsumoto K, Tomoshige K, Nagayasu T and Tsuchiya T. Designer umbilical cord-stemcells induce alveolar wall regeneration in pulmonary disease models, Frontiers in Immunology, 2024, April 15,1384718, doi: 10.3389/fimmu.2024.1384718
3) Hori A, Takahashi A, Miharu Y, Yamaguchi S, Sugita M, Mukai T, Nagamura F, and Nagamura-Inoue T, Superior migration ability of umbilical cord-derived mesenchymal stromal cells (MSCs) toward activated lymphocytes in comparison with those of bone marrow and adipose-derived MSCs, Front Cell Dev Biol. 2024 Mar 11;12:1329218,doi:10.3389/fcell.2024.1329218
4) Tsuji S, Mukai T, Tsuchiya H, Iwatani C, Nakamura A, Nagamura-Inoue T, Murakami T., Impact of administering umbilical cord-derived mesenchymal stem cells to cynomolgus monkeys with endometriosis, Reprod Med Biol. 2023 Sep 8;22(1):e12540. doi: 10.1002/rmb2.12540. eCollection 2023 Jan-Dec.
5) Tsuji M, Mukai T, Sato Y, Azuma Y, Yamamoto S, Cayetanot F, Bodineau L, OnodaA, Nagamura-Inoue T, Coq JO. Umbilical cord-derived mesenchymal stromal cell therapy to prevent the development of neurodevelopmental disorders related to low birth weight. Sci Rep. 2023 Mar 7;13(1):3841. doi: 10.1038/s41598-023-30817-3. PMID: 36882440; PMCID: PMC9992354.
6) Kagami H, Inoue M, Agata H, Asahina I, Nagamura-Inoue T, Taguri M, Tojo A. AClinical Study of Alveolar Bone Tissue Engineering Using Autologous Bone Marrow Stromal Cells: Effect of Optimized Cell-Processing Protocol on Efficacy. J Clin Med. 2022 Dec 9;11(24):7328. doi: 10.3390/jcm11247328. PMID: 36555944; PMCID:PMC9783548.
7) Meshitsuka S, Ninomiya R, Nagamura-Inoue T, Okada T, Futami M, Tojo A. CRISPR/Cas9 and AAV mediated insertion of β2 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy. Regen Ther. 2022 Oct 14;21:442-452. doi:10.1016/j.reth.2022.09.009. PMID: 36313397; PMCID: PMC9582586.
8) Nagamura-Inoue T, Kato S, Najima Y, Isobe M, Doki N, Yamamoto H, Uchida N, Takahashi A, Hori A, Nojima M, Ohashi K, Nagamura F, Tojo A. Immunological influence of serum-free manufactured umbilical cord-derived mesenchymal stromal cells for steroid-resistant acute graft-versus-host disease. Int J Hematol. 2022 Nov;116(5):754-769. doi: 10.1007/s12185-022-03408-7. Epub 2022 Jul 30. PMID: 35908021.
9) Ikeda K, Minakawa K, Yamahara K, Yamada-Fujiwara M, Okuyama Y, Fujiwara SI, Yamazaki R, Kanamori H, Iseki T, Nagamura-Inoue T, Kameda K, Nagai K, Fujii N, Ashida T, Hirose A, Takahashi T, Ohto H, Ueda K, Tanosaki R. Comparison of cryoprotectants in hematopoietic cell infusion-related adverse events. Transfusion. 2022 Jun;62(6):1280-1288. doi: 10.1111/trf.16877. Epub 2022 Apr 9. PMID: 35396716.
10) Kurogi H, Takijiri T, Sakumoto M, Isogai M, Takahashi A, Okubo T, Koike T, Yamada T, Nagamura-Inoue T, Sakaki-Yumoto M. Study on the Umbilical Cord-Mesenchymal Stem Cell Manufacturing Using Clinical-Grade Culture Medium. Tissue Eng Part C Methods. 2022 Jan;28(1):23-33. doi: 10.1089/ten.TEC.2021.0207. PMID: 35018815.
11) Asahina I, Kagami H, Agata H, Honda MJ, Sumita Y, Inoue M, Nagamura-Inoue T, Tojo A. Clinical Outcome and 8-Year Follow-Up of Alveolar Bone Tissue Engineering for Severely Atrophic Alveolar Bone Using Autologous Bone Marrow Stromal Cells with Platelet-Rich Plasma and β-Tricalcium Phosphate Granules. J Clin Med. 2021 Nov 10;10(22):5231. doi: 10.3390/jcm10225231. PMID: 34830513; PMCID: PMC8623501.
12) He H, Takahashi A, Mukai T, Hori A, Narita M, Tojo A, Yang T, Nagamura-Inoue T. The Immunomodulatory Effect of Triptolide on Mesenchymal Stromal Cells. Front Immunol. 2021 Aug 16;12:686356. doi: 10.3389/fimmu.2021.686356. PMID: 34484183; PMCID: PMC8415460.
13) Mukai T, Di Martino E, Tsuji S, Blomgren K, Nagamura-Inoue T, Ådén U. Umbilical cord-derived mesenchymal stromal cells immunomodulate and restore actin dynamics and phagocytosis of LPS-activated microglia via PI3K/Akt/Rho GTPase pathway. Cell Death Discov. 2021 Mar 15;7(1):46. doi: 10.1038/s41420-021-00436-w. PMID: 33723246; PMCID: PMC7961004.
14) Kurogi H, Takahashi A, Isogai M, Sakumoto M, Takijiri T, Hori A, Furuno T, Koike T, Yamada T, Nagamura-Inoue T, Sakaki-Yumoto M. Umbilical cord derived mesenchymal stromal cells in microcarrier based industrial scale culture sustain the immune regulatory functions. Biotechnol J. 2021 Jun;16(6):e2000558. doi: 10.1002/biot.202000558. Epub 2021 Apr 14. PMID: 33545746.
15) Ikeda K, Ohto H, Yamada-Fujiwara M, Okuyama Y, Fujiwara SI, Muroi K, Mori T, Kasama K, Kanamori H, Iseki T, Nagamura-Inoue T, Kameda K, Kanda J, Nagai K, Fujii N, Ashida T, Hirose A, Takahashi T, Minakawa K, Tanosaki R. Hematopoietic cell infusion-related adverse events in pediatric/small recipients in a prospective/multicenter study. Transfusion. 2020 May;60(5):1015-1023. doi:10.1111/trf.15786. Epub 2020 Apr 18. PMID: 32306410.
16) Mukai T, Tojo A, Nagamura-Inoue T. Mesenchymal stromal cells as a potential therapeutic for neurological disorders. Regen Ther. 2018 Aug 24;9:32-37. doi: 10.1016/j.reth.2018.08.001. PMID: 30525073; PMCID: PMC6222283.
17) Mukai T, Tojo A, Nagamura-Inoue T. Umbilical Cord-Derived Mesenchymal Stromal Cells Contribute to Neuroprotection in Neonatal Cortical Neurons Damaged by Oxygen-Glucose Deprivation. Front Neurol. 2018 Jun 15;9:466. doi: 10.3389/fneur.2018.00466. PMID: 29963009; PMCID: PMC6013549.
18) Nakamura S, Yokoyama K, Yusa N, Ogawa M, Takei T, Kobayashi A, Ito M, Shimizu E, Kasajima R, Wada Y, Yamaguchi R, Imoto S, Nagamura-Inoue T, Miyano S, Tojo A. Circulating tumor DNA dynamically predicts response and/or relapse in patients with hematological malignancies. Int J Hematol. 2018 Oct;108(4):402-410. doi: 10.1007/s12185-018-2487-2. Epub 2018 Jun 29. PMID: 29959746.
19) Ikeda K, Ohto H, Okuyama Y, Yamada-Fujiwara M, Kanamori H, Fujiwara SI, Muroi K, Mori T, Kasama K, Iseki T, Nagamura-Inoue T, Fujii N, Ashida T, Kameda K, Kanda J, Hirose A, Takahashi T, Nagai K, Minakawa K, Tanosaki R. Adverse Events Associated With Infusion of Hematopoietic Stem Cell Products: A Prospective and Multicenter Surveillance Study. Transfus Med Rev. 2018 Jun 1:S0887-7963(18)30023-3. doi: 10.1016/j.tmrv.2018.05.005. Epub ahead of print. PMID: 29891441.
20) Mukai T, Mori Y, Shimazu T, Takahashi A, Tsunoda H, Yamaguchi S, Kiryu S, Tojo A, Nagamura-Inoue T. Intravenous injection of umbilical cord-derived mesenchymal stromal cells attenuates reactive gliosis and hypomyelination in a neonatal intraventricular hemorrhage model. Neuroscience. 2017 Jul 4;355:175-187. doi: 10.1016/j.neuroscience.2017.05.006. Epub 2017 May 11. PMID: 28504197.
21) Mukai T, Nagamura-Inoue T, Shimazu T, Mori Y, Takahashi A, Tsunoda H, Yamaguchi S, Tojo A. Neurosphere formation enhances the neurogenic differentiation potential and migratory ability of umbilical cord-mesenchymal stromal cells. Cytotherapy. 2016 Feb;18(2):229-41. doi:10.1016/j.jcyt.2015.10.012. PMID: 26794714.
22) He H, Nagamura-Inoue T, Takahashi A, Mori Y, Yamamoto Y, Shimazu T, Tsunoda H, Tojo A. Immunosuppressive properties of Wharton's jelly-derived mesenchymal stromal cells in vitro. Int J Hematol. 2015 Sep;102(3):368-78. doi: 10.1007/s12185-015-1844-7. Epub 2015 Jul 31. PMID: 26228529.
23) Shimazu T, Mori Y, Takahashi A, Tsunoda H, Tojo A, Nagamura-Inoue T. Serum- and xeno-free cryopreservation of human umbilical cord tissue as mesenchymal stromal cell source. Cytotherapy. 2015 May;17(5):593-600. doi: 10.1016/j.jcyt.2015.03.604. PMID: 25881518.
24) Mori Y, Ohshimo J, Shimazu T, He H, Takahashi A, Yamamoto Y, Tsunoda H, Tojo A, Nagamura-Inoue T. Improved explant method to isolate umbilical cord-derived mesenchymal stem cells and their immunosuppressive properties. Tissue Eng Part C Methods. 2015 Apr;21(4):367-72. doi: 10.1089/ten.TEC.2014.0385. Epub 2015 Jan 7. PMID: 25220032.
25) Nagamura-Inoue T, He H. Umbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility. World J Stem Cells. 2014 Apr 26;6(2):195-202. doi: 10.4252/wjsc.v6.i2.195. PMID: 24772246; PMCID: PMC3999777.
26) He H, Nagamura-Inoue T, Tsunoda H, Yuzawa M, Yamamoto Y, Yorozu P, Agata H, Tojo A. Stage-specific embryonic antigen 4 in Wharton's jelly-derived mesenchymal stem cells is not a marker for proliferation and multipotency. Tissue Eng Part A. 2014 Apr;20(7-8):1314-24. doi: 10.1089/ten.TEA.2013.0333. Epub 2014 Mar 14. PMID: 24279891.
27) Ebihara Y, Takedani H, Ishige I, Nagamura-Inoue T, Wakitani S, Tojo A, Tsuji K. Feasibility of autologous bone marrow mesenchymal stem cells cultured with autologous serum for treatment of haemophilic arthropathy. Haemophilia. 2013 Mar;19(2):e87-9. doi: 10.1111/hae.12056. Epub 2012 Dec 4. PMID: 23205598.
28) Nagamura-Inoue T, Kai S, Azuma H, Takanashi M, Isoyama K, Kato K, Takahashi S, Taniguchi S, Miyamura K, Aoki K, Hidaka M, Nagamura F, Tojo A, Fang X, Kato S; Japan Cord Blood Bank Network. Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis. Bone Marrow Transplant. 2008 Aug;42(4):241-51. doi: 10.1038/bmt.2008.164. Epub 2008 Jun 23. PMID: 18574449.
29) Nagamura-Inoue T, Kodo H, Takahashi TA, Mugishima H, Tojo A, Asano S. Four cases of donor cell-derived AML following unrelated cord blood transplantation for adult patients: experiences of the Tokyo Cord Blood Bank. Cytotherapy. 2007;9(8):727-8. doi: 10.1080/14653240701466339. Epub 2007 Oct 4. PMID: 17917889.
30) Okada H, Nagamura-Inoue T, Mori Y, Takahashi TA. Expansion of Valpha24(+)Vbeta11(+) NKT cells from cord blood mononuclear cells using IL-15, IL-7 and Flt3-L depends on monocytes. Eur J Immunol. 2006 Jan;36(1):236-44. doi: 10.1002/eji.200526085. PMID: 16380959.
31) Nagamura-Inoue T, Mori Y, Yizhou Z, Watanabe N, Takahashi TA. Differential expansion of umbilical cord blood mononuclear cell-derived natural killer cells dependent on the dose of interleukin-15 with Flt3L. Exp Hematol. 2004 Feb;32(2):202-9. doi: 10.1016/j.exphem.2003.10.013. PMID: 15102482.
32) Zheng Y, Watanabe N, Nagamura-Inoue T, Igura K, Nagayama H, Tojo A, Tanosaki R, Takaue Y, Okamoto S, Takahashi TA. Ex vivo manipulation of umbilical cord blood-derived hematopoietic stem/progenitor cells with recombinant human stem cell factor can up-regulate levels of homing-essential molecules to increase their transmigratory potential. Exp Hematol. 2003 Dec;31(12):1237-46. doi: 10.1016/j.exphem.2003.08.016. PMID: 14662330.
33) Nagamura-Inoue T, Shioya M, Sugo M, Cui Y, Takahashi A, Tomita S, Zheng Y, Takada K, Kodo H, Asano S, Takahashi TA. Wash-out of DMSO does not improve the speed of engraftment of cord blood transplantation: follow-up of 46 adult patients with units shipped from a single cord blood bank. Transfusion. 2003Sep;43(9):1285-95. doi: 10.1046/j.1537-2995.2003.00486.x. PMID: 12919432.

総説（英語）
1) Nagamura-Inoue T, Nagamura F. , Umbilical cord blood and cord tissue banking as somatic stem cell resources to support medical cell modalities. Inflamm Regen. 2023 Dec 5;43(1):59. doi: 10.1186/s41232-023-00311-4.PMID: 38053217. Review.
2) Nagamura-Inoue T. [You can be a unique female physician scientist with originality to find the raison d'être in diverse career options in medicine]. Rinsho Ketsueki. 2022;63(8):934-936. Japanese. doi: 10.11406/rinketsu.63.934. PMID: 36058865.
3) Nagamura-Inoue T, Nagamura F. Umbilical cord blood and cord tissue banking as somatic stem cell resources to support medical cell modalities. Inflamm Regen. 2023 Dec 5;43(1):59. doi: 10.1186/s41232-023-00311-4. PMID: 38053217 Free PMC article. Review.
4) Mukai T, Sei K, Nagamura-Inoue T. Mesenchymal stromal cells: cell-based therapies for traumatic central nervous system injuries. J Integr Neurosci. 2022 Mar 18;21(2):44. doi: 10.31083/j.jin2102044. PMID: 35364632. Review.
5) Mukai T, Tojo A, Nagamura-Inoue T. Mesenchymal stromal cells as a potential therapeutic for neurological disorders. Regen Ther. 2018 Aug 24;9:32-37. doi: 10.1016/j.reth.2018.08.001. eCollection 2018 Dec. Review.
6) Shintaku H, Nabetani M, Hamazaki T, Kusuda S, Tamura M, Watabe S, Hayakawa M, Sato Y, Tsuji M, Taguchi A, Ichiba H, Oka A, Mori R, Taki A, Mukai T, Nagamura-Inoue T. Regenerative therapy for cerebral palsy: Transplantation of umbilical cord blood stem cells and umbilical cord mesenchymal stromal cells.　The journal of Hellenic Neurology. 2017, 26, 71.
7) Nagamura-Inoue T, Mukai T. Umbilical Cord is a Rich Source of Mesenchymal Stromal Cells for Cell Therapy. Curr Stem Cell Res Ther. 2016;11(8):634-642. doi: 10.2174/1574888x10666151026115017. PMID: 26496885.
8) Nagamura-Inoue T, He H. Umbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility. World J Stem Cells. 6:195-202, 2014.

書籍・雑誌（査読あり）
1) Nagamura-Inoue T,　同種臍帯由来間葉系細胞の治療, THE COMMENTARY日本再生医療学会雑誌　Vol 23 No.1 2-5, 2024
2) Nagamura-Inoue T, You can be a unique female physician scientist with originality to find the raison d'être in diverse career options in medicine, Rinsho Ketsueki. 2022;63(8):934-936. doi: 10.11406/rinketsu.63.934.
3) Nagamura-Inoue T, Nagamura F., Umbilical Cord Blood and Cord tissue bank as a source of allogeneic use, Novel Perspectives of Stem Cell Manufacturing and therapies, Edited by Diana Kitala and Ana Clotte Mauricio, IntechOpen, Chapter 3, 31-55, 2021, March 11, DOI: 10.5772/intechopen.91649.
4) Nagamura-Inoue T, Atsuta Y, Kodera Y, and Okamoto S, Chapter 13 “Transfusion”, Editor(s) name(s): Éliane Gluckman, Dietger Niederwieser and Mahmoud Aljurf., Establishing a Hematopoietic Stem Cell Transplantation Unit: A Practical Guide.183-195(2017).
5) Nagamura-Inoue T, Chapter 14, A new prospective cell therapy for neonatal brain injury, Cell Therapy For Perinatal Brain Injury. Chief Editor ; Shintaku H. (2017).
6) Nagamura-Inoue T, Mukai T, Chapter 7, Umbilical cord-derived mesenchymal stromal cells for perinatal brain injury, Cell Therapy For Perinatal Brain Injury. Chief Editor ; Shintaku H. (2017).